Lorlatinib

LORBRENA ® is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for: LORBRENA is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.
( 1, 2.1 )
Do not take if: LORBRENA is contraindicated in patients taking strong CYP3A inducers, due to the potential for serious hepatotoxicity.

Side effects, and when to stop

The following adverse reactions are described elsewhere in the labeling:

Risk of Serious Hepatotoxicity with Concomitant Use of Strong CYP3A Inducers
Central Nervous System Effects
Hyperlipidemia
Atrioventricular Block
Interstitial Lung Disease/Pneumonitis
Hypertension
Hyperglycemia

Who should not take it

LORBRENA is contraindicated in patients taking strong CYP3A inducers, due to the potential for serious hepatotoxicity.

Storing it

Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F).

Cite this page

NLM: sofidex [Internet]. Daloreum; c2026. Lorlatinib; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/lorlatinib
APA 7th: sofidex. (2026, August 3). Lorlatinib. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/lorlatinib
AMA 11th: Lorlatinib. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/lorlatinib

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.